<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509142</url>
  </required_header>
  <id_info>
    <org_study_id>IBS-FIM</org_study_id>
    <nct_id>NCT03509142</nct_id>
  </id_info>
  <brief_title>A First-in-Man Study of IBS</brief_title>
  <acronym>IBS-FIM</acronym>
  <official_title>A First-in-Man Study of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lifetech Scientific (Shenzhen) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lifetech Scientific (Shenzhen) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a pilot clinical trial for Sirolimus-eluting Iron Bioresorbable Coronary&#xD;
      Scaffold System（IBS）. The main purpose of this study is to evaluate the feasibility,&#xD;
      preliminary safety and efficacy of IBS. To provide the basis for subsequent large-scale,&#xD;
      multi-center, randomized controlled clinical trials of IBS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single-center, First-in-Man trial;&#xD;
&#xD;
      Study population: 45 subjects.&#xD;
&#xD;
      45 subjects will be randomly assigned into two cohorts: cohort 1(n=30), cohort 2(n=15)&#xD;
&#xD;
      The clinical follow up will be performed in all subjects at 1 month, 6 months, 1 year, 2&#xD;
      years, 3 years, 4 years, 5 years post procedure;&#xD;
&#xD;
      The Angiographic, Intra-Vascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT)&#xD;
      will be performed at 6 months and 2 years post procedure in cohort 1. The Angiographic, IVUS&#xD;
      and OCT will be performed at 1 year and 3 years post procedure in cohort 2.&#xD;
&#xD;
      The primary study endpoints:&#xD;
&#xD;
        1. Target lesion failure (TLF) at 6 months post procedure&#xD;
&#xD;
        2. Late Lumen Loss at 6 months post procedure&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Actual">July 19, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study Device related Composite Endpoint (Target Lesion Failure)</measure>
    <time_frame>6 months after implantation</time_frame>
    <description>Target Lesion Failure is defined as the composited endpoints of including cardiac death, Target vessel related myocardial infarction (TV-MI) and clinical indicated target lesion revascularization (CI-TLR), also known as MACE (major adverse cardiac events).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Late Lumen Loss</measure>
    <time_frame>6 months after implantation</time_frame>
    <description>Late Lumen Loss</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immediate Success Rate</measure>
    <time_frame>Immediate post procedure</time_frame>
    <description>Device Success:&#xD;
Successfully transit and release the IBS at target lesion, then withdraw the delivery system. Immediate residual stenosis &lt; 30% and TIMI blood flow is class 3 (visual).&#xD;
Lesion Success: Any method of intervention therapy, the residual stenosis of the target lesion &lt; 30% and TIMI blood flow is class 3(visual).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>Hospitalized period post procedure within 7 days</time_frame>
    <description>Defined as based on lesion success, there is no major adverse cardiac events in the hospitalization period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Evaluation of IBS</measure>
    <time_frame>Immediate post procedure</time_frame>
    <description>4 class (Excellent, good, general, bad) to evaluate the push ability, performance of through the lesions, performance of cover the lesions, support force, withdraw ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device related Composite Endpoint (DoCE)</measure>
    <time_frame>1 Month, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years post procedure</time_frame>
    <description>Target Lesion Failure, defined as the composited endpoints of including cardiac death, target vessel related myocardial infarction (TV-MI) and clinical indicated target lesion revascularization (CI-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient related Clinical Composite Endpoint (PoCE)</measure>
    <time_frame>1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years post procedure</time_frame>
    <description>Including all-cause mortality, all myocardial infarction and any revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis defined by ARC</measure>
    <time_frame>Acute (0-24 hours), Subacute (24 hours-30 days), Late (30 days-1 year), Very late (after 1 year)</time_frame>
    <description>Timing (acute, sub-acute, late and very late) Evidence (definite and probable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thickness of acute stent recoil (mm)</measure>
    <time_frame>Immediate post procedure</time_frame>
    <description>Angiographic Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent, in-segment, proximal and distal minimum lumen diameter (MLD)</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Angiographic Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent, in-segment, proximal and distal percent of diameter stenosis (DS, %)</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Angiographic Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent, in-segment, proximal and distal late lumen loss (LLL)</measure>
    <time_frame>1 year, 2 years, 3 years</time_frame>
    <description>Angiographic Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent, in-segment, proximal and distal angiographic defined restenosis (ABR)</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Angiographic Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasomotion</measure>
    <time_frame>6 months,1 year, 2 years, 3 years</time_frame>
    <description>Defined as the average diameter change of lumen diameter before and after using nitroglycerin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of neointimal thickness by OCT</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Optical Coherence Tomography Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of proportion of strut coverage by OCT</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Optical Coherence Tomography Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of incomplete strut apposition by OCT</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Optical Coherence Tomography Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of percentage area obstruction by OCT</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Optical Coherence Tomography Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of healing score by OCT</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Optical Coherence Tomography Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of late recoil by OCT</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Optical Coherence Tomography Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of vessel area by IVUS</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Intra-Vascular Ultrasound Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of lumen area by IVUS</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Intra-Vascular Ultrasound Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of scaffold area by IVUS</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Intra-Vascular Ultrasound Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of neointimal area by IVUS</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Intra-Vascular Ultrasound Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of percentage area obstruction by IVUS</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Intra-Vascular Ultrasound Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of volumetric obstruction by IVUS</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Intra-Vascular Ultrasound Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of late recoil area by IVUS</measure>
    <time_frame>Immediate post procedure, 6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Intra-Vascular Ultrasound Endpoint</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Single Coronary Vessel Disease</condition>
  <arm_group>
    <arm_group_label>IBS implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of IBS in patients with coronary artery lesions. All the subjects will be assigned to cohort 1 (n=30) and cohort 2 (n=15).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System</intervention_name>
    <description>Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)</description>
    <arm_group_label>IBS implantation</arm_group_label>
    <other_name>IBS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients participating in this clinical trial must meet the following criteria:&#xD;
&#xD;
          1. Age of 18-75, males or non pregnancy females;&#xD;
&#xD;
          2. Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina,&#xD;
             post-infarct angina or silent ischemia) suitable for elective PCI;&#xD;
&#xD;
          3. One target lesion, and target lesion can be completely covered by a single stent;&#xD;
&#xD;
          4. Target lesion length ≤ 18 mm, target lesion diameter between 3.0 mm to 3.5 mm&#xD;
             (visual);&#xD;
&#xD;
          5. Visual assessment of target lesion stenosis ≥70%, TIMI blood flow≥ 1;&#xD;
&#xD;
          6. Subject who understand the purpose of testing, voluntary and informed consent,&#xD;
             patients undergoing invasive imaging follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded if any of the following conditions apply:&#xD;
&#xD;
        General:&#xD;
&#xD;
          1. Within 1 week of any acute myocardial infarction or myocardial enzymes did not return&#xD;
             to normal;&#xD;
&#xD;
          2. Implantation of stent in target vessel within 1 year, patients with planned&#xD;
             intervention again within six months;&#xD;
&#xD;
          3. Patients who had coronary artery bypass (coronary artery bypass grafting);&#xD;
&#xD;
          4. Patients with contraindications for coronary artery bypass graft surgery;&#xD;
&#xD;
          5. Severe heart failure (NYHA class III and above) or left ventricular ejection&#xD;
             fraction&lt;40% (ultrasonic or left ventricular angiography);&#xD;
&#xD;
          6. Preoperative renal function: serum creatinine &gt; 2.0 mg/dl or 177 mu mol/L; receiving&#xD;
             hemodialysis;&#xD;
&#xD;
          7. Patients had ischemic stroke half a year before implantation, patients had transient&#xD;
             ischemic attack 3 months before implantation, patients have high coagulation tendency&#xD;
             judged by investigator or laboratory examination;&#xD;
&#xD;
          8. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage,&#xD;
             contraindications on antiplatelet agents and anticoagulant therapy; patients would not&#xD;
             allow to undergoing antithrombotic therapy;&#xD;
&#xD;
          9. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer, rapamycin and&#xD;
             metal allergies;&#xD;
&#xD;
         10. Patients who have a history of disease related to iron overload or iron disorder, such&#xD;
             as hereditary hemochromatosis, etc;&#xD;
&#xD;
         11. The patient's life expectancy is less than 12 months;&#xD;
&#xD;
         12. Patient participated in other drug or medical device study and does not meet the&#xD;
             primary study endpoint in clinical trials time frame;&#xD;
&#xD;
         13. Poor compliance and patients unable to complete the study in accordance with the&#xD;
             requirements;&#xD;
&#xD;
         14. Patient with heart transplant;&#xD;
&#xD;
         15. The unstable arrhythmia, such as high risk ventricular extra systole and ventricular&#xD;
             tachycardia;&#xD;
&#xD;
         16. Cancer needs chemotherapy;&#xD;
&#xD;
         17. Patients of immune suppression, autoimmune diseases, planned or undergoing&#xD;
             immunosuppressive therapy;&#xD;
&#xD;
         18. Planning or being receiving long-term anticoagulant therapy, such as heparin,&#xD;
             warfarin, etc;&#xD;
&#xD;
         19. With six months for elective surgery requires stop using aspirin and clopidogrel;&#xD;
&#xD;
         20. Blood test prompted platelet count &lt; 100 x 10^9/L, or &gt; 700 x 10^9/L, white blood&#xD;
             cells &lt; 3 x 10^9/L, or abnormal liver function (ALT, AST 3 times greater than normal&#xD;
             range);&#xD;
&#xD;
         21. Patients with diffuse peripheral vascular disease; cannot use 6F catheter;&#xD;
&#xD;
         22. Patients with valvular surgery in the past.&#xD;
&#xD;
        Exclusion criteria by angiography:&#xD;
&#xD;
          1. Chronic total occlusion (TIMI blood flow=0 before implantation) , left main coronary&#xD;
             artery lesion, ostial lesion, multiple vessel lesion, branch lesion and bridge lesion&#xD;
             which branch vessel diameter ≥ 2.0 mm (if the ostium of branch vessel stenosis &gt;40% or&#xD;
             needs balloon predilation); visible thrombus in target vessels;&#xD;
&#xD;
          2. Severe calcified lesions and distorted disease which unable to predilation, lesion not&#xD;
             suitable for stent delivery and expansion;&#xD;
&#xD;
          3. In-stent restenosis;&#xD;
&#xD;
          4. Myocardial bridge is involved in target lesion;&#xD;
&#xD;
          5. In order to reach the target lesion, study stent has to go through the previous&#xD;
             implanted stent;&#xD;
&#xD;
          6. Predilation balloon can't expand completely in target lesion site, judgment standard&#xD;
             for fully expansion as below, patients are excluded when do not meet any item:&#xD;
&#xD;
        A.DS% &lt; 40% (visual), highly recommend DS% ≤20% B.TIMI blood flow= class 3 (visual) C.No&#xD;
        angiography complications (e.g., distal embolization, lateral branch closed) D.No&#xD;
        interlining level NHLBI type D - F E.No continuous chest pain (&gt; 5 minutes), and F.No lower&#xD;
        or higher ST segment &gt;5 minutes.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Runlin Gao</last_name>
    <role>Study Chair</role>
    <affiliation>Fu Wai Hospital, Beijing, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Fuwai hospital</name>
      <address>
        <city>Peking</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

